Literature DB >> 28506618

The PTZ kindling mouse model of epilepsy exhibits exploratory drive deficits and aberrant activity amongst VTA dopamine neurons in both familiar and novel space.

Mahboubeh Ahmadi1, Jean-Philippe Dufour2, Erich Seifritz3, Javad Mirnajafi-Zadeh4, Bechara J Saab5.   

Abstract

Recurrent seizures that define epilepsy are often accompanied by psychosocial problems and cognitive deficits with incompletely understood aetiology. We therefore used the pentylenetetrazol (PTZ) kindling model of epilepsy in mice to examine potential seizure-associated neuropathologies, focusing on motivation, memory and novel-environment-induced activation of midbrain dopaminergic neurons. In addition to recurrent seizures, we found that PTZ kindling led to a strong suppression of novelty-driven exploration while largely sparing fear-driven exploration. The deficits in exploratory drive may be relevant for other cognitive impairments since reduced unassisted rearing in a learning arena correlated with poorer spatial memory of object location. Using c-Fos immunofluorescence as a marker of neuronal activity, we observed that dopamine neurons within the ventral tegmental area (VTA) of PTZ kindled mice demonstrate hyperactivity at baseline and hypoactivity in response to a novel environment compared to saline-injected cagemate controls. These data extend previous findings of PTZ kindling-mediated disruptions of hippocampal processes important for novel environment recognition and learning by demonstrating PTZ kindling also induces motivational deficits that are associated with reduced stimulus-evoked activation of VTA dopamine neurons. More broadly, these data help understand the aetiology of complex behavioural changes in the PTZ kindling model, and may assist in the development of superior diagnoses and treatments for epilepsy.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Curiosity; Epilepsy; Exploration; Mice; New frontier task (NFT); Ventral tegmental area (VTA)

Mesh:

Substances:

Year:  2017        PMID: 28506618     DOI: 10.1016/j.bbr.2017.05.025

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  6 in total

1.  Genetic backgrounds have unique seizure response profiles and behavioral outcomes following convulsant administration.

Authors:  Nycole Ashley Copping; Anna Adhikari; Stela Pavlova Petkova; Jill Lynn Silverman
Journal:  Epilepsy Behav       Date:  2019-11-04       Impact factor: 2.937

Review 2.  The role of the basal ganglia in the control of seizure.

Authors:  J Vuong; Annaelle Devergnas
Journal:  J Neural Transm (Vienna)       Date:  2017-08-01       Impact factor: 3.575

Review 3.  PTZ kindling model for epileptogenesis, refractory epilepsy, and associated comorbidities: relevance and reliability.

Authors:  Tanveer Singh; Awanish Mishra; Rajesh Kumar Goel
Journal:  Metab Brain Dis       Date:  2021-08-24       Impact factor: 3.584

4.  Therapeutic potential of Pak1 inhibition for pain associated with cutaneous burn injury.

Authors:  Yiqun Guo; Curtis Benson; Myriam Hill; Stefanie Henry; Philip Effraim; Stephen G Waxman; Sulayman Dib-Hajj; Andrew M Tan
Journal:  Mol Pain       Date:  2018-06-29       Impact factor: 3.395

5.  A single seizure selectively impairs hippocampal-dependent memory and is associated with alterations in PI3K/Akt/mTOR and FMRP signaling.

Authors:  Andrew J Holley; Samantha L Hodges; Suzanne O Nolan; Matthew Binder; James T Okoh; Kaylin Ackerman; Lindsey A Tomac; Joaquin N Lugo
Journal:  Epilepsia Open       Date:  2018-10-28

6.  Antagonism of Histamine H3 receptors Alleviates Pentylenetetrazole-Induced Kindling and Associated Memory Deficits by Mitigating Oxidative Stress, Central Neurotransmitters, and c-Fos Protein Expression in Rats.

Authors:  Alaa Alachkar; Sheikh Azimullah; Mohamed Lotfy; Ernest Adeghate; Shreesh K Ojha; Rami Beiram; Dorota Łażewska; Katarzyna Kieć-Kononowicz; Bassem Sadek
Journal:  Molecules       Date:  2020-03-30       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.